Nanobiotix S.A. (NBTX)
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Nanobiotix S.A.
| Form | Description | Links | |
|---|---|---|---|
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 13G/A | |||
| 6-K | |||
| 13G/A | |||
| S-8 | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| FWP | |||
| 424B5 | |||
| FWP | |||
| 6-K | |||
| 6-K | |||
| 6-K |
1-25 of 311 filings
Recent SEC filings with analysis
- 6-KNanobiotix announced final data from the Phase 1 Study 1100 evaluating JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant advanced…
- 6-KNanobiotix filed a routine Form 6-K disclosing its share capital and voting rights as of September 30, 2026, in compliance with French Commercial Code and AMF…
- 6-KNanobiotix announced on October 1, 2026 the appointment of Arnd Christ as chief financial officer and executive board member, effective the same day.
- 6-KNanobiotix reported a H1 2026 net loss of €34.3 million versus €5.4 million a year earlier, with the wider loss driven mainly by €14.5 million of interest…
- 6-KNanobiotix reported H1 2026 results with €5.6 million in revenue and other income versus €26.6 million a year ago; the decline is largely explained by a €21.2…
- 6-KNanobiotix filed a routine 6-K disclosing its monthly voting rights and share capital figures in compliance with French Commercial Code and AMF regulations.
- 6-KNanobiotix announced complete full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, presented at the IASLC…